Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
Phase 1
Active, not recruiting
- Conditions
- Recurrent Anaplastic Large Cell LymphomaRefractory Anaplastic Large Cell LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Mature T- and NK-Cell Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides
- Interventions
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT03278782
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate AdenocarcinomaStage IIIA Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8
- Interventions
- Biological: Gonadotropin-releasing Hormone AnalogProcedure: Radical Prostatectomy
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT03279250
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Glutamine PET Imaging Colorectal Cancer
Phase 1
Active, not recruiting
- Conditions
- RAS Wild TypeStage IVB Colorectal CancerStage IVA Colorectal CancerStage IV Colorectal Cancer
- Interventions
- Procedure: Positron Emission TomographyProcedure: Blood Draw
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT03275974
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Loss of INI 1 Protein ExpressionStage III Renal Cell Cancer AJCC v8Kidney Medullary CarcinomaStage IV Renal Cell Cancer AJCC v8
- Interventions
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT03274258
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
Phase 2
Recruiting
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaPhiladelphia Chromosome PositiveBCR-ABL1 Fusion Protein ExpressionRefractory Acute Lymphoblastic Leukemiat(9;22)
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT03263572
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men with AVPC
Phase 2
Active, not recruiting
- Conditions
- Prostate Cancer AggressivenessProstate Carcinoma
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 119
- Registration Number
- NCT03263650
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
Phase 1
Active, not recruiting
- Conditions
- Recurrent Diffuse Large B-Cell LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory T-Cell Non-Hodgkin LymphomaRefractory Hodgkin Lymphoma
- Interventions
- Procedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacokinetic Study
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03259503
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
Phase 2
Terminated
- Conditions
- Malignant Neoplasms of Ill-defined Secondary and Unspecified SitesMalignant Neoplasms of Lip Oral Cavity and PharynxOropharyngeal Cancer
- Interventions
- Biological: ISA101b
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT03258008
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
Phase 1
Active, not recruiting
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT03247088
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Mind-Body Intervention in Glioma Couples
Not Applicable
Active, not recruiting
- Conditions
- Low Grade GliomaMalignant GliomaMetastatic Malignant Neoplasm in the BrainGlioblastomaPartnerWHO Grade III Glioma
- Interventions
- Other: Quality-of-Life AssessmentProcedure: Mind-Body Intervention ProcedureOther: Questionnaire Administration
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT03244995
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath